BioXcel Therapeutics (BTAI) FCF Margin (2022 - 2026)
BioXcel Therapeutics (BTAI) recorded quarterly FCF Margin of 5732.52% in Q1 2026, down 3.27% quarter-over-quarter from 5550.78% in Q4 2025, and up 143593.0% on a YoY basis from N/an in Q1 2025.
BioXcel Therapeutics (BTAI) FCF Margin (2022 - 2026) Analysis & Trends
BioXcel Therapeutics' FCF Margin history runs 5 years deep, the most recent figure standing at 5732.52% for Q1 2026.
- In Q1 2026, FCF Margin rose 143593.0% year-over-year to 5732.52%; the TTM figure through Mar 2026 stood at 8438.38% (down 485501.0% YoY), while the FY2025 annual figure was 8974.3%, down 579570.0% from the prior year.
- FCF Margin was 5732.52% for Q1 2026 at BioXcel Therapeutics, down from 5550.78% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 2099.09% in Q2 2024 to a low of 25414.08% in Q1 2023.
- Historically, FCF Margin has averaged 10390.81% across 5 years, with a median of 7634.58% in 2024.
- The sharpest annual moves came in 2024 and 2025: FCF Margin surged 2237181 bps in 2024, then plunged 1153583 bps in 2025.
- A 5-year view of FCF Margin shows it stood at 16234.87% in 2022, then jumped by 56 bps to 7144.41% in 2023, then jumped by 43 bps to 4046.17% in 2024, then slumped by 37 bps to 5550.78% in 2025, then fell by 3 bps to 5732.52% in 2026.
- The last three FCF Margin figures came in at 5732.52% (Q1 2026), 5550.78% (Q4 2025), and 19170.41% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | -5.22% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 12.86% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 46.39% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 16.78% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | -2.77% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -429.96% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 13.24% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 32.62% |
| 10 | BioXcel Therapeutics | 25.46 Mn | 25.46 Mn | -77,000.00 | -5,732.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5,732.52% |
| Dec 31, 2025 | -5,550.78% |
| Sep 30, 2025 | -19,170.41% |
| Jun 30, 2025 | -10,479.17% |
| Mar 31, 2025 | -7,168.45% |
| Dec 31, 2024 | -4,046.17% |
| Sep 30, 2024 | -7,634.58% |
| Jun 30, 2024 | -2,099.09% |
| Mar 31, 2024 | -3,042.27% |
| Dec 31, 2023 | -7,144.41% |
| Sep 30, 2023 | -11,021.70% |
| Jun 30, 2023 | -8,360.18% |
| Mar 31, 2023 | -25,414.08% |
| Dec 31, 2022 | -16,234.87% |
| Sep 30, 2022 | -22,763.50% |